News
Objectives Low-level laser therapy (LLLT) is not recommended in major knee osteoarthritis (KOA) treatment guidelines. We investigated whether a LLLT dose–response relationship exists in KOA. Design ...
The mean maximum pain intensity during the day and night at the end of treatment and at the follow-up sessions one and three months after treatment showed a significantly (p<0.0001) greater reduction ...
Osmol Therapeutics E.U. Patent Allowance for Novel Therapy Targeting Chemotherapy-induced Neuropathy
NEW HAVEN, Conn., June 16, 2025 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced ...
Osmol Therapeutics is a privately held, clinical stage biopharma company focused on developing a treatment to prevent neuropathy and cognitive impairment caused by many chemotherapy and ADC treatments ...
NEW HAVEN, Conn., June 16, 2025 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy ...
NEW HAVEN, Conn., June 16, 2025 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced ...
Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Peripheral Neuropathy Treatment Market 2025-2029" has been added to ResearchAndMarkets.com's offering. Powered by Money.com - Yahoo may earn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback